Identification, Mitigation, and Disclosure of Relevant Financial Relationships

As an accredited provider of continuing education, Vizient, Inc. is dedicated to ensuring this activity presents learners with only accurate, balanced, scientifically justified recommendations, and is free from promotion, marketing, and commercial bias. In accordance with The Standards for Integrity and Independence in Accredited Continuing Education, all planners, faculty, and others in control of the educational content have disclosed the absence or existence of all financial relationships (of any dollar amount) with ineligible companies within the past 24 months.

It is Vizient’s policy that owners and employees of ineligible companies, and any individuals who refuse to disclose the absence or existence of financial relationships with any ineligible companies are disqualified from participating as planners or faculty.

Absence of Relevant Financial Relationships

Vizient, Inc., Jointly Accredited for Interprofessional Continuing Education, defines companies to be ineligible as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

An individual is considered to have a relevant financial relationship if the educational content an individual can control is related to the business lines or products of the ineligible company.

No one in a position to control the content of this educational activity have relevant financial relationships with ineligible companies.

Faculty

Brian Bohn, PharmD, BCPS

Clinical Pharmacy Specialist- Infectious Diseases

Barnes Jewish Hospital

Trang Trinh, PharmD, MPH, BCPS, BCIDP

Associate Professor of Clinical Pharmacy

UCSF School of Pharmacy

Yang Zhao, PharmD, BCPS

Clinical Pharmacy Specialist – Infectious Diseases

Sentara Norfolk General Hospital

Planning committee

Shannon Smallwood, PharmD, BCPS

Sr. Pharmacy Executive

Vizient, Inc

John Schoen, PharmD, BCPS

Sr. Clinical Manager of Drug Information

Vizient, Inc

Joseph M. Geskey, DO, MBA, MS-PopH

DO, MBA, MS-PopH

Principal, Data Science & Member Insights • Vizient Inc

Vizient, Inc.

Statement of content validity

Vizient, Inc. educational activities are intended to assist healthcare teams advance their professional responsibilities in accordance with the definition of continuing education. It is the policy of Vizient, Inc. to review and ensure that all content and recommendations for patient care within accredited CE is evidenced-based, based on current science and clinical reasoning while ensuring the content is fair and balanced. All recommendations must conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation. Vizient, Inc. does not permit accredited continuing education if it advocates for unscientific approaches to diagnosis or therapy, or if the education promotes recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.

FDA off-label/unapproved usage

Faculty/Presenters are required to identify any new and evolving topics for which there is a lower/absence of evidence base. This is to ensure that our content does not advocate for, or promote, practices that are not, or not yet adequately based on current science, evidence, and clinical reasoning. Faculty/Presenters are required to disclose any discussion of (1) off-label/unapproved or investigational uses of FDA approved commercial products or devices and/or (2) products or devices not yet approved in the United States.

Tran Trinh – Will be discussing off-label use of antibiotics

Yang Zhao – Will be discussing combination treatment approaches 2/avibactam for NDM and steno infections

Disclaimer: The education provided through this activity is for continuing education purposes only. The views and opinions expressed in this activity are those of the faculty/presenters and do not necessarily reflect the views of Vizient, Inc.